MERS Vaccine Candidate Offers Promise, but Questions Remain  by Menachery, Vineet D.
EBioMedicine 2 (2015) 1292–1293
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comCommentaryMERS Vaccine Candidate Offers Promise, but Questions RemainVineet D. Menachery
Departments of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USADOI of original article: http://dx.doi.org/10.1016/j.ebi
E-mail address: vineet@email.unc.edu.
http://dx.doi.org/10.1016/j.ebiom.2015.09.037
2352-3964/© 2015 The Author. Published by Elsevier B.Va r t i c l e i n f o were ﬁrst achieved for MERS-CoV in rhesus macaques (FalzaranoArticle history:
Received 21 September 2015
Accepted 22 September 2015





et al., 2014). Subsequently, other large animalmodels have been report-
ed including marmosets, camels, rabbits, and alpacas and vary in their
levels of MERS-CoV pathogenesis (van Doremalen and Munster,
2015).While new small animalmodels have been described and contin-
ue to be developed, in the short term, non-human primates provide the
best model for testing vaccines and therapeutics.
In these issues of EBioMedicine, Lan and colleagues describe vaccine
studies in a non-human primate model of MERS-CoV infection (Lan
et al., 2015). Building on previous studies in rhesus macaques withimmunity following vaccination and boost. Subsequent intra-trachealMiddle East respiratory syndrome coronavirus (MERS-CoV), a novel
human virus that emerged in 2012, has caused signiﬁcant respiratory
disease and kindled fears of a SARS-like epidemic traversing the world
(Hilgenfeld and Peiris, 2013). While lacking the rapid human-to-
human spread seen with its SARS-CoV cousin, the outbreak of MERS-
CoV has continued in the Middle East over the past three years and
has lead to infection in 26 countries, N1500 cases, and N550 deaths
(WHO, 2015). With periodic reintroduction from zoonotic sources and
the possibility for further human adaptation, MERS-CoV remains a sig-
niﬁcant global public health threat and highlights the need for thera-
peutic countermeasures to limit infection and spread.
Despite several years of study, understanding ofMERS-CoV infection
has been limited by a variety of factors including difﬁculty accessing
samples, limited autopsy data, and the lack of robust animal models of
disease (Zumla et al., 2015). However, a number of reports have provid-
ed both insights and tools for further study including extensive se-
quencing data, reverse genetic resources, and monoclonal antibodies
for treatment of infection (Zumla et al., 2015). In contrast, vaccine strat-
egies have been limited due to the absence of robust animal models.
Typically examined in mice, the presence of speciﬁc charge and glyco-
sylation difference between human and rodent DPP4, the receptor for
MERS-CoV, prevent infection (Peck et al., 2015). Therefore, the tradi-
tional approaches to study pathogenesis and vaccine efﬁcacy have
been stunted. The lack of a small animal model has shifted MERS-CoV
research into larger in vivomodels including non-human primates and
ungulates (van Doremalen and Munster, 2015). Koch's postulatesom.2015.08.031.
. This is an open access article underSARS-CoV (Wang et al., 2012), the report details the efﬁcacy of a
MERS vaccine based on a recombinant receptor binding domain (RBD)
subunit. Their results indicate stimulation of both humoral and cellular
challenge of vaccinated monkeys revealed partial protection from
MERS-CoV induced pathogenesis including reduced pneumonia and
viral titers. Having been tested for both SARS and MERS-CoV, the plat-
form has potential as a rapid response vaccine approach for future
emergent CoV outbreaks. Similarly, the platform could also be deployed
in reservoir populations like camels that are thought to harbor the virus
(Zumla et al., 2015). However, this RBD-based vaccine failed to produce
sterilizing immunity typically sought in the context of vaccination.
Overall, the results demonstrate that in the rhesusmacaquemodel, sub-
unit vaccines that target the receptor-binding domain of MERS-CoV can
offer some level of protection, but require further reﬁnement to induce
sterilizing immunity.
While the study shows promise for the receptor binding domain-
based vaccine platforms, a number of other questions remain. The
rhesus macaque model, which supports MERS-CoV replication, fails to
recapitulate severe disease seen in humans. As such, the level of protec-
tion in these studies may underestimate the utility of the approach or,
alternatively, provides only minor protection for human disease. Fur-
ther study in more pathogenic models like the marmoset or with
adapted viruses is required to decipher this question. Similarly, while
the RBD-based platform drives protection, other aspects of vaccine efﬁ-
cacy cannot be tested in themacaquemodel. Previous workwith a dou-
ble inactivated SARS-CoV had shown efﬁcacy in young mice (Spruth
et al., 2006); however, subsequent analysis in aged animals or with het-
erologous challenge revealed vaccine failure and signiﬁcant immune
pathology (Bolles et al., 2011). While not tested in experimental sys-
tems, based on reported cases, age and immuno-compromised status
appears to be co-morbidity factors for MERS-CoV infection and lethality
(Hilgenfeld and Peiris, 2013; Zumla et al., 2015). Therefore, testing the
efﬁcacy of any vaccine in aged and immune compromised populationsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1293V.D. Menachery / EBioMedicine 2 (2015) 1292–1293must be considered. In addition, the continued reintroduction of MERS-
CoV fromzoonotic sources increases the likelihood of exposure to heter-
ologous virus. With the focus of this vaccine on the RBD of MERS, the
possibility of vaccine-induced immune pathology is reduced; however,
in vivo testing is required to conﬁrm this result.
Overall, the report by Lan and colleagues details a promising MERS-
RBD-based platform for vaccine development. The combination of
strong neutralization and reduced pathogenesis in the rhesusmacaques
indicates that the approach is worth pursuing. However, additional
studies are required in models that can capture pathogenesis seen in
humans, efﬁcacy in aged populations, and possibility of immune pathol-
ogy due to heterologous challenge. Despite these caveats, the success of
the RBD-based approach has important implications for both MERS
treatment as well as for rapid vaccine development platforms for future
emergent CoV outbreaks.
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